Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice (Q34556831)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice (English)

1 reference

Europe PubMed Central

3 August 2017

author name string

José Pedro Henriques Patrício

1

1 reference

Europe PubMed Central

3 August 2017

Jorge Pinto Pereira Barbosa

2

1 reference

Europe PubMed Central

3 August 2017

Rui Miguel Monteiro Ramos

3

1 reference

Europe PubMed Central

3 August 2017

Nuno Filipe Pimenta Antunes

4

1 reference

Europe PubMed Central

3 August 2017

Pedro Carlos Santos de Melo

5

1 reference

Europe PubMed Central

3 August 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

3 August 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

3 August 2017

33

1 reference

Europe PubMed Central

3 August 2017

3

1 reference

Europe PubMed Central

3 August 2017

167-183

1 reference

Europe PubMed Central

3 August 2017

Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Prostaglandins in health and disease: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

NSAID-induced gastrointestinal and cardiovascular injury

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Characterization of etoricoxib, a novel, selective COX-2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

A review of the gastrointestinal safety data--a gastroenterologist's perspective

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Long-term safety concerns with proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Uso apropiado de los antiinflamatorios no esteroideos en reumatología: documento de consenso de la Sociedad Española de Reumatología y el Colegio Mexicano de Reumatología

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cyclooxygenase inhibition and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Stroke risk and NSAIDs: a systematic review of observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

A trial of adjuvant therapy in colorectal cancer: the VICTOR trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Harmful effects of NSAIDs among patients with hypertension and coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Ag

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0052-6

21 January 2018

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the WHO analgesic ladder still valid? Twenty-four years of experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NSAID prescribing precautions

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using NSAIDs in cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoricoxib for arthritis and pain management

1 reference

https://pubmed.ncbi.nlm.nih.gov/23338974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0052-6

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34556831&oldid=1554673830"